+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Kidney Cancer Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 148 Pages
  • June 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1882088
Description Jump to:
The global market for Kidney Cancer Drugs was estimated at US$6.1 Billion in 2024 and is projected to reach US$8.1 Billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Kidney Cancer Drugs market.

Global Kidney Cancer Drugs Market - Key Trends and Drivers Summarized

Kidney cancer, a complex disease characterized by variable behavior and response to treatments, requires a nuanced approach based on the specific characteristics of the tumor. Initial treatment strategies range from surgical interventions in early stages to advanced pharmacological treatments in later stages, including biological and targeted therapies designed to control the growth and spread of cancer cells. Biological therapies interfere with tumor growth by targeting specific molecules, while targeted therapies focus on molecular targets that are crucial for cancer cell proliferation and survival. These advanced therapies have significantly transformed the treatment landscape for kidney cancer, offering new hope and prolonged control over the disease for many patients. Ongoing research aims to optimize these treatments, enhancing their effectiveness and integrating them into comprehensive treatment regimes.

The treatment of advanced kidney cancer has been revolutionized by Tyrosine Kinase Inhibitors (TKIs) and immunotherapies that target critical aspects of cancer progression. TKIs, such as sunitinib and pazopanib, block enzymes essential for cancer cell growth and tumor blood supply, effectively starving and inhibiting tumor development. Immunotherapies like nivolumab disrupt cancer cells` ability to evade the immune system, enhancing the body's natural immune response against cancer cells. The development of combination therapies, which pair drugs like nivolumab with other agents such as ipilimumab or TKIs, is proving to further enhance treatment efficacy, offering improved outcomes for patients with advanced kidney cancer. These treatment strategies necessitate thorough discussions between patients and healthcare providers to carefully weigh the benefits and risks, along with considerations for new clinical trials that offer access to emerging therapies.

The market for kidney cancer drugs is driven by multiple factors that contribute to its growth and evolution. Technological advances in drug development, spurred by molecular biology and cancer genomics, allow for more targeted and effective therapies with fewer side effects, fostering a shift towards precision medicine tailored to specific genetic profiles of patients and tumors. Regulatory support, including accelerated approvals for breakthrough therapies and incentives for orphan drugs, aids in the rapid introduction of innovative treatments. The integration of artificial intelligence in drug development streamlines the discovery and testing of new drugs, reducing time and cost. Collaborations among pharmaceutical companies, biotechnology firms, and academic institutions enhance the development pipeline. Moreover, there is an increasing preference for outpatient cancer therapies that offer convenience and reduce hospital visits. Patient advocacy and enhanced awareness lead to earlier diagnosis and treatment, while economic growth and better insurance coverage support the adoption of new, often costly, treatments. Global health trends, including rising obesity and hypertension rates, further drive the demand for effective kidney cancer treatments, shaping a dynamic market poised for continued innovation and growth.

Scope of Study:

The report analyzes the Kidney Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:
  • Segments: Therapeutic Class (Targeted Therapy, Immunotherapy); Pharmacologic Class (Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2))
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Targeted Therapy segment, which is expected to reach US$5.6 Billion by 2030 with a CAGR of a 5.1%. The Immunotherapy segment is also set to grow at 4.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.6 Billion in 2024, and China, forecasted to grow at an impressive 8.1% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Kidney Cancer Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Kidney Cancer Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Kidney Cancer Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Novartis International AG and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 12 companies featured in this Kidney Cancer Drugs market report include:

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Kidney Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Kidney Cancer Propels Demand for Effective Treatment Options
Increasing Awareness and Early Diagnosis of Kidney Cancer Accelerates Market Penetration
Advances in Targeted Therapy and Immunotherapy Strengthen Business Case for Innovative Kidney Cancer Drugs
Focus on Personalized Medicine Drives Adoption of Precision Kidney Cancer Drugs
Growing Geriatric Population and Associated Cancer Risk Spurt Growth in Kidney Cancer Drugs Market
Introduction of Combination Therapies Throws the Spotlight on Enhanced Treatment Efficacy
Advances in Biomarker Identification Propel Development of Targeted Kidney Cancer Drugs
Focus on Minimizing Side Effects and Improving Quality of Life Sustains Demand for Innovative Drugs
Growing Adoption of Oral Chemotherapy Drugs Expands Treatment Options for Patients
Advances in Molecular Diagnostics Propel Growth in Precision Medicine for Kidney Cancer
Increasing Number of Clinical Trials and Pipeline Drugs Enhance Market Potential
Expansion of Telemedicine and Remote Patient Monitoring Drives Market Adoption
Focus on Patient-Centric Care Models Generates Demand for Personalized Kidney Cancer Treatments
Advances in Drug Delivery Systems Propel Development of Novel Kidney Cancer Therapies
Rising Prevalence of Lifestyle-Related Risk Factors Expands Addressable Market Opportunity
Development of Biosimilars and Generics Throws the Spotlight on Affordable Treatment Options
Increasing Focus on Integrative and Complementary Therapies Drives Demand for Holistic Treatment Approaches
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 2: World Historic Review for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 3: World 15-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 5: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 6: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 8: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 9: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 11: World Historic Review for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 12: World 15-Year Perspective for Angiogenesis Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 14: World Historic Review for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 15: World 15-Year Perspective for mTOR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 17: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 18: World 15-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 20: World Historic Review for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 21: World 15-Year Perspective for Cytokine Immunotherapy (IL-2) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 22: World Kidney Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
III. MARKET ANALYSIS
UNITED STATES
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 24: USA Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: USA 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: USA 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
CANADA
TABLE 29: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: Canada 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 32: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: Canada 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
JAPAN
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 35: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Japan 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 38: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Japan 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
CHINA
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 41: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: China Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: China 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 44: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: China 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
EUROPE
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 47: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Europe 15-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Europe 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Europe 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
FRANCE
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 56: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: France Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: France 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 59: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: France 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
GERMANY
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 62: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Germany 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 65: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Germany 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
ITALY
TABLE 68: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Italy 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 71: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Italy 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
UNITED KINGDOM
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 74: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: UK Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: UK 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 77: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: UK 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
SPAIN
TABLE 80: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Spain Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Spain 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 83: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Spain 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
RUSSIA
TABLE 86: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Russia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Russia 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 89: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Russia 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Rest of Europe 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Rest of Europe 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Asia-Pacific 15-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Asia-Pacific 15-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Asia-Pacific 15-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2015, 2025 & 2030
AUSTRALIA
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

Table Information

Report AttributeDetails
No. of Pages148
PublishedJune 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.1 Billion
Compound Annual Growth Rate4.8%
Regions CoveredGlobal

Related Topics

Related Reports

Kidney Cancer Drugs Market by Treatment Type, Mechanism of Action, Line of Therapy, Route of Administration, Dosage Form, End User - Global Forecast to 2030 - Product Image

Kidney Cancer Drugs Market by Treatment Type, Mechanism of Action, Line of Therapy, Route of Administration, Dosage Form, End User - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Kidney Cancer Therapeutics and Diagnostics Market Report by Component, Cancer Types, Application, and Region 2025-2033 - Product Image

Kidney Cancer Therapeutics and Diagnostics Market Report by Component, Cancer Types, Application, and Region 2025-2033

  • Report
  • 125 Pages
  • Global
From
Kidney Cancer Therapeutics and Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Kidney Cancer Therapeutics and Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 140 Pages
  • Global
From
Advanced Renal Cell Carcinoma - Pipeline Insight, 2025 - Product Image

Advanced Renal Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.